scholarly journals Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors

BMC Urology ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Liancheng Fan ◽  
Baijun Dong ◽  
Chenfei Chi ◽  
Yanqing Wang ◽  
Yiming Gong ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Prospective Study ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Single Centre ◽  
Castration Resistant

Potential prognostic factors for metastatic castration resistant prostate cancer with Abiraterone Acetate

2018 ◽  
Vol 17 (14) ◽  
pp. e2865
Author(s):  
C. Melo Alvim Moreira ◽  
A. Mansinho ◽  
R. Paiva ◽  
R. Brás ◽  
P. Semedo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Prognostic factors for castration-resistant prostate cancer in men treated with abiraterone acetate

2016 ◽  
Vol 15 (13) ◽  
pp. e1674
Author(s):  
M. Yasui ◽  
Y. Kumano ◽  
K. Uemura ◽  
S. Yoneyama ◽  
T. Kawahara ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16569-e16569
Author(s):  
Carla Cavaliere ◽  
Orazio Caffo ◽  
Cinzia Ortega ◽  
Carmine D'aniello ◽  
Marilena DI Napoli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals PROSABI: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with abiraterone acetate (AA)

2017 ◽  
Vol 28 ◽  
pp. v293
Author(s):  
D. Lorente Estelles ◽  
J. Puente ◽  
A. Medina ◽  
R. Lozano Mejorada ◽  
L. Rivera ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Multi Centre Study ◽  
Centre Study ◽  
Castration Resistant

scholarly journals Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors

2021 ◽  
Vol 41 (8) ◽  
pp. 3955-3968
Author(s):  
MIGUEL E. JIMENEZ ROMERO ◽  
MARIA CAMACHO GALLEGO ◽  
JOSE C. NAVARRO SERRATO ◽  
MIGUEL A. SANCHEZ HURTADO ◽  
JOSE D. SANTOTORIBIO
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Comparison of the oncological outcomes of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer: A multicenter real-life data

2021 ◽  
Author(s):  
Ayşe Demirci ◽  
Cemil Bilir ◽  
Burcu Gülbağcı ◽  
İlhan Hacibekiroğlu ◽  
İbrahim V.Bayoğlu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Specific Antigen ◽  
Real Life ◽  
Progression Free Survival ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Factors Affecting ◽  
Castration Resistant ◽  
Number Of Patients

Abstract Background: To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: A total of 250 patients treated with E or AA in 5 centers were included.Results: The number of patients with no prostate specific antigen (PSA) decline was higher in the AA group than that in the E group, and the proportion of patients with a PSA decline of ≥50% was higher in the E group (p = 0.020). The rate of progression in the AA group (82.2%) was significantly higher than that in the E group (p <0.001). Radiological progression free survival (rPFS) and overall survival (OS) were significantly longer in the E group when compared to that in the AA group (p <0.001 and p = 0.027, respectively). In the E group, rPFS was significantly longer than that in the AA group in both pre- and post-docetaxel settings (p=0.010 and p=0.003, respectively). OS was similar in the pre-docetaxel setting; but in the post-docetaxel setting, E group had a significantly longer OS than the AA group(p=0.021). In the multivariate analysis performed in the whole patient group, we found that good prognostic factors for rPFS were E treatment, being ≥75 years and a PSA decline of ≥50% while there was no factor affecting OS. Conclusion: With longer OS and PFS, E seems to be more suitable for mCRPC patients in the post-docetaxel setting than AA.

Sign in / Sign up

Export Citation Format

Share Document